Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BRD9 is a critical regulator of androgen receptor signaling and prostate cancer progression - RNA-Seq

ABSTRACT: Standard RNA-Seq analysis from LNCaP cells treated with shBRD9 for 3d, shBRD9 for 11d, or 3 µM IBRD9 for 3d.

ORGANISM(S): Homo sapiens

PROVIDER: GSE146624 | GEO | 2020/12/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression.

Project description:Switch/sucrose-nonfermentable (SWI/SNF) chromatin-remodeling complexes are critical regulators of chromatin dynamics during transcription, DNA replication, and DNA repair. A recently identified SWI/SNF subcomplex termed GLTSCR1/1L-BAF (GBAF; or "noncanonical BAF", ncBAF) uniquely contains bromodomain-containing protein BRD9 and glioma tumor suppressor candidate region 1 (GLTSCR1) or its paralog GLTSCR1-like (GLTSCR1L). Recent studies have identified a unique dependency on GBAF (ncBAF) complexes in synovial sarcoma and malignant rhabdoid tumors, both of which possess aberrations in canonical BAF (cBAF) and Polybromo-BAF (PBAF) complexes. Dependencies on GBAF in malignancies without SWI/SNF aberrations, however, are less defined. Here, we show that GBAF, particularly its BRD9 subunit, is required for the viability of prostate cancer cell lines in vitro and for optimal xenograft tumor growth in vivo. BRD9 interacts with androgen receptor (AR) and CCCTC-binding factor (CTCF), and modulates AR-dependent gene expression. The GBAF complex exhibits overlapping genome localization and transcriptional targets as bromodomain and extraterminal domain-containing (BET) proteins, which are established AR coregulators. Our results demonstrate that GBAF is critical for coordinating SWI/SNF-BET cooperation and uncover a new druggable target for AR-positive prostate cancers, including those resistant to androgen deprivation or antiandrogen therapies. SIGNIFICANCE: Advanced prostate cancers resistant to androgen receptor antagonists are still susceptible to nontoxic BRD9 inhibitors, making them a promising alternative for halting AR signaling in progressed disease.

| S-EPMC8026650 | biostudies-literature

BRD9 is a regulator of androgen receptor signaling and prostate cancer progression - ChIP-Seq

Project description:BRD9 and BRD4 ChIP-Seq in LNCaP prostate cancer cells

2020-12-28 | GSE146623 | GEO

BRD9 is a regulator of androgen receptor signaling and prostate cancer progression

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-12-28 | GSE146625 | GEO

Identification of drivers and therapeutic vulnerabilities in anti-androgen resistant prostate cancer cells

Project description:Inhibition of the androgen receptor (AR) by anti-androgens is the standard treatment for castration resistant prostate cancer (CRPC), but it inevitably leads to the development of resistance. We generated two multi anti-androgen resistant cell-line models by treatment of LNCaP cells with enzalutamide (ResA) and RD-162 (ResB). Both cell-lines have an AR independent, non-neuroendocrine phenotype. To identify the resistance mechanisms we performed RNASeq analysis. To this end, the three cell-lines were plated in medium with 5% dextran-coated charcoal (DCC) treated FCS at a density of 1 million cells/well in 6-well plates. After 24 hours of steroid starvation the cells were treated with 10 nM of the androgen dihydrotestosterone (DHT), 10 µM of the anti-androgen enzalutamide, a combination of the two, or vehicle (DMSO) for 18 hours.

2019-09-26 | GSE130534 | GEO

BRD9 is a critical regulator of androgen receptor signaling and prostate cancer progression - RNA-Seq

Project description:BRD9 is a critical regulator of androgen receptor signaling and prostate cancer progression - RNA-Seq

| PRJNA611535 | ENA

ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer

Project description:Chromosomal translocations juxtaposing the androgen-responsive TMPRSS2 promoter with the ETS-family transcription factor ERG result in aberrant ERG up-regulation in approximately 50% of prostate cancers. Studies to date have demonstrated important roles of ERG in inducing oncogenic properties of prostate cancer. Its molecular mechanisms of action, however, are yet to be fully understood. To address these questions, we generated engineered LNCaP cells with ERG overexpression followed by LEF1 knockdown as well as control cell lines. To further investigate the role of LEF1 in ERG fusion positive samples, we also knockdown ERG in VCaP cell line. We performed microarray analysis on LNCaP cells with ERG overexpression followed by LEF1 knockdown using siRNA. We also knockdown endogenous ERG in fusion-positive cell line VCaP.

2013-05-29 | E-GEOD-47423 | biostudies-arrayexpress

BRD9 is a regulator of androgen receptor signaling and prostate cancer progression

Project description:BRD9 is a regulator of androgen receptor signaling and prostate cancer progression

| PRJNA611525 | ENA

Elk1 Directs a Critical Component of Growth Signaling by the Androgen Receptor in Prostate Cancer

Project description:Elk1 directs selective gene induction that is a substantial and critical component of growth signaling by AR in PC cells. Gene expression in LNCaP cells was determined in androgen-depleted medium in response to R1881 in ELK1 knock down (via AR shRNA) or in cells treated with control shRNA.

2013-05-02 | E-GEOD-34589 | biostudies-arrayexpress

Androgen Receptor Degraders Overcome Common Resistance Mechanisms Developed During Prostate Cancer Treatment

Project description:RNA-sequencing of VCaP and LNCaP, LNCaP-EnzR, or LNCaP AR-V7 overexpressing prostate cancer cell lines treated with AR degrader ARD-61.

2020-01-12 | GSE137833 | GEO

ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer

2013-05-29 | GSE47423 | GEO